IBCSG as part of ETOP IBCSG Partners Foundation is one of the world’s leading groups in breast cancer research. IBCSG pioneers research in combined hormonal therapy and chemotherapy, timing and duration of adjuvant therapies and quality of life of breast cancer patients. The latest generation of clinical trials in the adjuvant setting addresses tailored treatment for subgroups of patients, as we also expand our research into neoadjuvant treatment, chemotherapy and immunotherapy for advanced disease. In addition to clinical trials, ETOP IBCSG Partners Foundation conduct extensive programs in translational research, database studies, quality of life and statistical methodology. We conducts clinical trials at the highest level of knowledge in breast cancer medicine, trial methodology, data handling, and ethical principles. Formed in 1977 as the Ludwig Breast Cancer Study Group, the International Breast Cancer Study Group is dedicated to innovative clinical research to improve the prognosis of women with breast cancer. Patients and investigators from six continents (Europe, Australia/New Zealand, Africa, Asia, North and South America) cooperate by participating in extensive clinical trials in breast cancer populations.

ETOP IBCSG Partners Foundaton

As of July 1, 2021, the two highly respected clinical and translational cancer research foundations ETOP (European Thoracic Oncology Platform) and IBCSG (International Breast Cancer Study Group) have merged to form the joint entity ETOP IBCSG Partners Foundation. The new foundation brings together two strong and equal partners. By joining forces, the position as an international academic research organization is further strengthened www.etop.ibcsg.org.

Patients at the
Focus of our Research

The goal of clinical research within ETOP IBCSG Partners Foundation is to give our patients a longer survival and symptom-free period after primary treatment, and to improve their quality of life. We aim to translate the results of our trials into tailored treatments for individual women depending on their age and characteristics of their cancer. We serve this purpose by also combining our clinical, molecular and pathological findings in order to contribute to the growing field of translational research.

Download more Information

ETOP IBCSG Partners Annual Report 2022

ETOP IBCSG Partners Jahresbericht 2021

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login